IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase 3 study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC

Date

22 Oct 2018

Session

Proffered paper session- NSCLC, metastatic

Presenters

Federico Cappuzzo

Authors

F. Cappuzzo1, M. McCleod2, M. Hussein3, A. Morabito4, A. Rittmeyer5, H.J. Conter6, H. Kopp7, D. Daniel8, S. McCune9, T. Mekhail10, A. Zer11, N. Reinmuth12, A. Sadiq13, V. Archer14, T. Ochi Lohmann15, L. Wang16, M. Kowanetz17, W. Lin18, A. Sandler19, H. West20

Author affiliations

  • 1 Dipartimento Di Oncologia Medica, Azienda Unità Sanitaria Locale della Romagna, 48100 - Ravenna/IT
  • 2 Sarah Cannon Research Institute, Florida Cancer Specialists, Fort Myers/US
  • 3 Sarah Cannon Research Institute, Florida Cancer Specialists, Leesburg/US
  • 4 Thoracic Medical Oncology, Istituto Nazionale Tumori, IRCCS “Fondazione G. Pascale”, Naples/IT
  • 5 Department Of Thoracic Oncology, Lungenfachklinik Immenhausen, Immenhausen/DE
  • 6 Department Of Medicine, William Osler Health System, Ontario/CA
  • 7 Robert Bosch Centrum Für Tumorerkrankungen (rbct), Klinik Schillerhöhe, Stuttgart/DE
  • 8 Medical Oncology, Tennessee Oncology, Chattanooga/US
  • 9 Northwest Georgia Oncology Centers, Marietta Cancer Center, Marietta/US
  • 10 Medical Oncology, Florida Hospital Cancer Institute, Orlando/US
  • 11 Thoracic Oncology Unit, Rabin Medical Center, Tel Aviv University, Tel Aviv/IL
  • 12 Thoracic Oncology, Asklepios Clinics Munich-Gauting, Gauting/DE
  • 13 Fort Wayne Medical, Oncology and Haematology, Fort Wayne/US
  • 14 Pd Oncology, Roche Products Limited, Welwyn Garden City/GB
  • 15 Pd Oncology, F. Hoffmann-La Roche Ltd, Basel/CH
  • 16 Biostatistics, Genentech Inc, South San Francisco/US
  • 17 Oncology Biomarker Development, Genentech Inc, 94080 - South San Francisco/US
  • 18 Clincial Science, Genentech, Inc, South San Francisco/US
  • 19 Clinical Science, Genentech Inc, 94080 - South San Francisco/US
  • 20 Thoracic Oncology Program, Swedish Cancer Institute, Seattle/US
More

Resources

Background

Atezo (anti-PD-L1) monotherapy improves overall survival (OS) vs docetaxel in 2L+ NSCLC, regardless of PD-L1 status; phase 3, 1L studies have shown the clinical benefit of atezo plus chemotherapy. IMpower130 (NCT02367781) evaluated atezo + CnP vs CnP in patients (pts) with measurable (RECIST v1.1) stage IV non-squamous NSCLC.

Methods

Pts (randomised 2:1) received atezo (1200 mg IV q3w) + CnP (carboplatin: AUC 6 q3w; nab-paclitaxel: 100 mg/m2 IV qw) (Arm A) or CnP (Arm B), for 4 or 6 21-day cycles and maintenance (Arm A: atezo until loss of clinical benefit; Arm B: best supportive care or pemetrexed q3w until disease progression [PD]). Crossover to atezo at PD was initially permitted for Arm B pts. Co-primary endpoints: investigator-assessed PFS and OS (ITT-WT population: EGFR-WT/ALK-negative). Secondary endpoints: OS and PFS (ITT population and by PD-L1 expression), response rate and safety. ITT population could be formally tested for OS/PFS if ITT-WT OS was positive.

Results

723 ITT (679 ITT-WT) pts were enrolled. Statistically significant, clinically meaningful improvements in OS and statistically significant improvements in PFS (ITT and ITT-WT) were observed in Arm A vs Arm B (table). PFS and OS benefit was observed in all PD-L1 subgroups, and consistently across all subgroups, except in pts with liver metastases and EGFR/ALK genomic alterations. In treated pts, 73.2% (Arm A) vs 60.3% (Arm B) had grade 3–4 treatment-related adverse events.

Table. IMpower130 Efficacy Analyses

Arm A
Atezo + CnP

Arm B
CnP

ITT-WT

n=451

n=228

Median OS (95% CI)

18.6 mo (16.0–21.2)

13.9 mo (12.0–18.7)

HR (95% CI; P value)

0.79 (0.64–0.98; 0.033)

12-mo OS (95% CI)

63.1% (58.59–67.66)

55.5% (48.89–62.17)

Median PFS (95% CI)

7.0 mo (6.2–7.3)

5.5 mo (4.4–5.9)

HR (95% CI; P value)

0.64 (0.54–0.77; <0.0001)

12-mo PFS (95% CI)

29.1% (24.83–33.44)

14.1% (9.37–18.76)

n=447

n=226

Confirmed ORR (investigator assessed) (95% CI)

49.2% (44.49–53.96)

31.9% (25.84–38.36)

n=220

n=72

Median DOR (95% CI)

8.4 mo (6.9–11.8)

6.1 mo (5.5–7.9)

PD-L1 higha

n=88

n=42

Median OS (95% CI)

17.4 mo (14.78–NA)

16.9 mo (10.94–NA)

HR (95% CI)

0.84 (0.51–1.39)

Median PFS (95% CI)

6.4 mo (5.49–9.76)

4.6 mo (3.22–7)

HR (95% CI)

0.51 (0.34–0.77)

PD-L1 lowa

n=128

n=65

Median OS (95% CI)

23.7 mo (18.63–NA)

15.9 mo (12.32–25.63)

HR (95% CI)

0.70 (0.45–1.08)

Median PFS (95% CI)

8.3 mo (7.16–10.35)

6.0 mo (5.29–6.93)

HR (95% CI)

0.61 (0.43–0.85)

PD-L1 negativea

n=235

n=121

Median OS (95% CI)

15.2 mo (12.88–19.15)

12.0 mo (8.97–17.71)

HR (95% CI)

0.81 (0.61–1.08)

Median PFS (95% CI)

6.2 mo (5.52–7.16)

4.7 mo (4.11–5.72)

HR (95% CI)

0.72 (0.56–0.91)

ITT

n=483

n=240

Median OS (95% CI)

18.1 mo (15.3–20.8)

13.9 mo (12.0–18.2)

HR (95% CI; P value)

0.80 (0.65–0.99; 0.039)

Median PFS (95% CI)

7.0 mo (6.3–7.3)

5.6 mo (4.5–5.9)

HR (95% CI; P value)

0.65 (0.54–0.77; <0.0001)

a PD-L1 high (TC3 or IC3): Patients with PD-L1 expression in ≥50% of tumour cells or ≥10% of tumour-infiltrating immune cells; PD-L1 low (TC1/2 or IC1/2): Patients with PD-L1 expression in ≥1% and <50% of tumour cells or ≥1% and <10% of tumour-infiltrating immune cells; and PD-L1 negative (TC0 and IC0): Patients with PD-L1 expression in <1% of tumour cells and <1% of tumour-infiltrating immune cells. Data cut-off: 15 March 2018. Minimum follow up: 13 months. NCT02367781.

DOR, duration of response; HR, hazard ratio; IC, immune cells; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; TC, tumour cells.

Conclusions

Overall, IMpower130 showed statistically significant, clinically meaningful improvements in OS and statistically significant improvements in PFS with atezo + CnP, vs CnP, in 1L, stage IV non-squamous NSCLC, in this predominantly ITT-WT population. No new safety signals were identified.

Clinical trial identification

NCT02367781 (20 February 2015).

Editorial Acknowledgement

Support for third-party writing assistance for this abstract, furnished by Islay Steele, PhD, of Health Interactions, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings